Physical Wellness

No Trace Of Cancer Left On Man Who Was Given 18 Months To Live

By Anne Collins | Update Date: Feb 06, 2017 08:50 AM EST

Terminally ill Bob Berry, 60, who had lung cancer, has been left with no trace of the disease. He is one of three people to take part in the trial at The Christie who have tested a new drug. He is also one out of the 12 who tested the drug across the globe.

Bob is from Hazel Grove in Stockport. He was suffering pains in his shoulder and was diagnosed with lung cancer three years ago. He underwent surgery to remove the tumor but doctors said it was too late as the cancer grew and spread to his lymph nodes.

He was referred to The Christie for treatment where he began radiotherapy and chemotherapy. Unfortunately, it was unsuccessful. Bob was not responding to the drugs and was told he only had a year and a half left to live.

iTV reported the doctors decided to transfer him to the clinical trials unit of the hospital and last year he became one of the first people to be treated with the brand new drug. It was the first human trial.

The drug cannot be named yet but has been studied at only six centers worldwide. The treatment is a combination of the drug and immunotherapy.

According to The Sun, Dr. Matthew Krebs, Bob's consultant at The Christie, one of the largest cancer treatment centres in Europe said "Bob has had a phenomenal response to taking part in this clinical trial. His most recent scans show that he's had a complete response with no apparent trace of tumour in his body."

Bob will be monitored closely and will continue to have regular scans so that researchers can assess how durable his response would be. Dr. Krebs said that further research would be necessary for this brand new drug. Since the trial involved different studies they will have to establish how the findings can help more cancer patients in the future.

He added "cancer is a complex disease and not every patient responds as well as" Bob has.

© 2023 Counsel & Heal All rights reserved. Do not reproduce without permission.

Join the Conversation

Real Time Analytics